Catalent completes Paragon buyout for $1.2 bln

Catalent Inc has closed its previously announced acquisition of Paragon Bioservices Inc, a producer of biopharmaceuticals and vaccines, for $1.2 billion. In connection with the deal, Catalent has issued $650 million of convertible preferred stock to Leonard Green & Partners LP. Paragon's backers included NewSpring Capital and Camden Partners.

DealsNorth AmericaUSHealthcareBriefs